| DOI: 10.29090/psa.2026.02.26.9358 | Pharm Sci Asia 2026; 53(2), 195-202 |
Prescription of dipeptidyl peptidase-4 inhibitor–containing regimens and their effectiveness in blood glucose control among Vietnamese outpatients with type 2 diabetes mellitusThuan Thi Minh Nguyen1*, Ngoc Thi Bao Le1, Thanh Duong Thien Nguyen2, Thao Thi Thanh Vo2
1 Department of Biochemistry, School of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Viet Nam
2
Dong Nai General Hospital, Viet Nam
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that is increasing in prevalence and is a leading cause of death due to cardiovascular, renal, and neurological complications. Dipeptidyl peptidase-4 inhibitors (DPP-4i) have been increasingly used due to their ability to provide stable glycemic control and their suitability for elderly patients. The aim of this study was to investigate the effectiveness of treatment regimens containing DPP-4 inhibitor in outpatients with T2DM. A retrospective descriptive study conducted over 6 months, compared pre- and post-treatment outcomes on 308 T2DM outpatients who were prescribed DPP-4 inhibitors at Dong Nai General Hospital from January 2024 to May 2025. Results showed that the median age of patients was 67 years, with a higher proportion of females than males (60.4%). Most patients had comorbidities such as lipid disorder (93.2%) and hypertension (73.4%). The DPP-4 inhibitors prescribed were primarily sitagliptin and vildagliptin, administered at doses appropriate to renal function. Metformin, insulin, and sulfonylureas were the most commonly co-administered drugs with DPP-4 inhibitors. Following the DPP-4 inhibitor–based regimen, mean HbA1c decreased by 0.7%, FBG decreased by 0.94 mmol/L, and the proportion of patients achieving HbA1c < 7% increased to 28.2%, which was statistically significant (p < 0.05). In conclusion, DPP-4 inhibitors demonstrated a moderate glucose-lowering effect, making them suitable for elderly T2DM patients with comorbidities or a high risk of hypoglycemia. Drug use adhered to clinical guidelines and was appropriate in most cases.
Keyword:
Type 2 diabetes mellitus; Dipeptidyl peptidase-4 inhibitors; HbA1c; Fasting blood glucose; Outpatients
Download full paper (PDF File size: 504.72 KB.)
|
